-
公开(公告)号：US20240122917A1
公开(公告)日：2024-04-18
申请号：US18263191
申请日：2022-01-26
发明人： Yao HUA , Lei WANG , Zhengping ZHANG , Rong CHEN , Shibao YANG
IPC分类号： A61K31/4709 , A61K31/4152 , A61P9/10
CPC分类号： A61K31/4709 , A61K31/4152 , A61P9/10
摘要： Disclosed is the use of a composition containing cilostazol or a pharmaceutically acceptable salt thereof and edaravone in the preparation of a drug for treating cerebrovascular diseases, especially ischemic cerebrovascular diseases. The experiment result shows that the tail vein administration of 1-15 mg/kg of cilostazol or 1.67-8.33 mg/kg of edaravone on rats with a focal cerebral ischemia-reperfusion injury can significantly ameliorate neurological defects in rats with an MCAO and reduce a cerebral infarction area; and performing compound combination within the dosage range (the mass ratio of cilostazol:edaravone is 1:5 to 5:1) can be synergistic. The tail vein administration of 3.33-16.67 mg/kg of cilostazol or 3.33-16.67 mg/kg of edaravone on mice with a focal cerebral ischemia-reperfusion injury can significantly ameliorate neurological defects in mice with an MCAO and reduce a cerebral infarction area.
-
2.发明公开公开(公告)号：US20240082234A1
公开(公告)日：2024-03-14
申请号：US18271991
申请日：2022-01-12
发明人： Yao HUA , Lei WANG , Zhengping ZHANG , Rong CHEN , Shibao YANG
IPC分类号： A61K31/4709 , A61K31/045 , A61P9/10
CPC分类号： A61K31/4709 , A61K31/045 , A61P9/10
摘要： The present invention belongs to the pharmaceutical field, and relates to an application of a cilostazol and d-borneol composition in preparing a drug for treating cerebrovascular disease, in particular ischemic cerebrovascular disease. The present invention specifically relates to a composition containing cilostazol or a pharmaceutically acceptable salt thereof and d-borneol, and an application of the composition in preparing a drug for treating cerebrovascular disease, in particular ischemic cerebrovascular disease.
-
搜索结果
2 条记录 (耗时 0.01 秒)
